Prof. Arjan Bredenoord and Dr. Evan Dellon emphasize the need to assess multiple disease domains to get the complete picture of patients’ EoE.
Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss disease modification in severe asthma, including what disease modification is, how it can be identified, and how the advent of biologics may bring about disease modification.

Learn about patient concerns in EoE and the benefits of adequate monitoring and effective maintenance therapy on disease control and QoL
Profs. Greuter, Savarino, and Giordano discuss multidimensional EoE assessment, tailoring long-term care to patient needs, and recent clinical data.
Join Dr. Aceves and Ms. Ugras as they share their insights on how to identify potential patients with EoE and the importance of early diagnosis.
Dr Tzivinikos discusses the importance of early identification and management of pediatric EoE to improve long-term outcomes
Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP
Prof. Salvatore Oliva discusses the latest clinical data for EoE that included patients from childhood to adulthood.
Learn how a food bolus impaction event can help identify a patient with EoE and the importance of multiple disease domains in assessing EoE.

Join leading experts in pediatric eosinophilic esophagitis (EoE), Professors Salvatore Oliva, MD, PhD, and André Hörning, MD, as they explore the multifaceted journey of pediatric patients with EoE through a hypothetical patient case, navigating real-world challenges in managing EoE.

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

Dr. Donna Culton discusses the elevated mortality risk in patients with bullous pemphigoid at EADV 2025